HCN Oncology Essentials: ICI Therapy | HCC New Surgical Options | Docs Refute NCCN Prostate Cancer GuidelinesNovember 09, 2021 | Oncology Hematology Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy In this cohort study of 34,131 patients with cancer published in JAMA Oncology, trial ineligibility was associated with a greater likelihood of immune checkpoint inhibitor (ICI) monotherapy use compared with non-ICI therapy. Among trial-ineligible patients, there were no overall survival differences between treatment with ICI monotherapy, ICI combination therapy, and non-ICI therapy. Read full article Gastroenterology Drug Combination Gets Advanced Liver Cancer Patients to Surgery Research from Johns Hopkins Kimmel Cancer Center showed that combination therapy of cabozantinib and nivolumab could make curative surgery possible for some liver cancer patients who would normally not be considered for such a procedure. Among 15 people with hepatocellular carcinoma (HCC) in the study who could not be treated previously with surgery, the drugs allowed 12 patients to undergo successful surgical removal of their cancer. Five of these 12 patients had only 10% or less of their tumor remaining after the drug treatment. Read full article Internal Medicine Docs Disagree with Update to NCCN Guidelines for Prostate Cancer The updated NCCN guidelines no longer say that active surveillance is “preferred” for low-risk prostate cancer, prompting some physicians to claim this recommendation may encourage overtreatment and is a “step back” from progress made over the last decade, which has been defined by active surveillance as the preferable care option for most low-risk localized prostate cancer patients. Read full article
CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH